AOD-9604
Modified fragment of human growth hormone (hGH 176-191) that mimics fat-burning effects without growth-promoting side effects.
Category
Fat Burning / Metabolic
Frequency
Daily injection
Research
Phase 2 CompletedWhat is AOD-9604?
AOD-9604 (Advanced Obesity Drug) is a synthetic peptide fragment derived from the C-terminus of human growth hormone — specifically amino acids 176–191. Researchers isolated this portion of hGH because it appears to be responsible for the fat-metabolizing properties of growth hormone without the growth-promoting or insulin-desensitizing effects.
It was originally developed by Monash University in Australia and reached Phase 2b clinical trials for obesity treatment. While it did not receive FDA approval (results were modest as a standalone treatment), it has become popular in the biohacking community for its targeted fat-loss properties with a very favorable safety profile.
Unlike GLP-1 peptides, AOD-9604 does not suppress appetite — it works directly on fat tissue to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage). It is particularly valued for targeting stubborn fat deposits.
How It Works
Lipolysis Stimulation: AOD-9604 binds to beta-3 adrenergic receptors on fat cells, stimulating the breakdown of stored triglycerides into free fatty acids that can be burned for energy. This process is called lipolysis.
Lipogenesis Inhibition: Simultaneously inhibits the conversion of food into stored fat, reducing fat accumulation particularly in adipose tissue.
No IGF-1 Elevation: Unlike full hGH, AOD-9604 does not stimulate IGF-1 production, meaning it does not cause muscle growth, bone density changes, or glucose dysregulation — making it significantly safer for long-term use.
Benefits
- Targeted fat reduction, particularly stubborn fat deposits
- Stimulates lipolysis (fat breakdown) directly in adipose tissue
- Does not cause insulin resistance or glucose issues
- No IGF-1 elevation — safer than full hGH
- Cartilage repair properties observed in some studies
- Daily injection protocol is simple and well-tolerated
- Good safety profile demonstrated in human clinical trials
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Standard | 250–300mcg | Once daily (fasted, morning) | 8–12 weeks |
| Advanced | 500mcg | Split: morning + pre-workout | 8–12 weeks |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Injection site redness or swelling (mild)
- ⚠Brief flushing or warmth post-injection
- ⚠Mild fatigue in first 1–2 weeks
Rare
- •Headache (typically transient)
- •Dizziness immediately post-injection
- •Nausea (uncommon at standard doses)
Who Should NOT Use AOD-9604
- ✕Active cancer or history of cancer (growth factors)
- ✕Pregnancy or breastfeeding
- ✕Under 18 years old
- ✕Active diabetes (monitor blood glucose)
- ✕Allergy to peptide components
What to Expect
Minimal visible changes. Body adapts to the peptide. Some users report reduced water retention early on.
Fat loss becomes more noticeable, particularly in stubborn areas. Best results when taken fasted in the morning and combined with cardio.
Cumulative fat reduction continues. Most noticeable in abdominal and love handle areas. Lean mass preserved.
Consolidation phase. Results are most visible now. Many users cycle off and assess before running another cycle.
FAQ
Q: Should I take AOD-9604 fasted?
A: Yes — fasted morning injection maximizes efficacy. Insulin blunts growth hormone signaling, so taking AOD-9604 after overnight fast with at least 30 minutes before eating amplifies the lipolytic effect.
Q: How does AOD-9604 compare to GLP-1 peptides for weight loss?
A: GLP-1 peptides (Retatrutide, Tirzepatide) typically produce more total weight loss because they suppress appetite dramatically. AOD-9604 works best as a complement — targeting fat tissue directly while GLP-1s reduce caloric intake. They stack well.
Q: Can AOD-9604 help with spot reduction?
A: Spot reduction is largely a myth for exercise, but AOD-9604 may come closest to targeted fat loss among peptides. Users consistently report preferential loss in stubborn abdominal and hip fat, though total caloric deficit still drives overall results.
Where to Get AOD-9604 in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
View Supply Index